An article in the Feb. 18, 2004, issue of BioWorld Today should have said Cortex Pharmaceuticals Inc.'s partner Les Laboratoires Servier invested $6 million into clinical trials of CX516.

 

Editor's Note: The correction has been made in BioWorld Online.